<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN" "http://jats.nlm.nih.gov/publishing/1.1d3/JATS-journalpublishing1.dtd">
<article article-type="research-article" dtd-version="1.1d3" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="pmc">plosone</journal-id>
<journal-title-group>
<journal-title>PLOS ONE</journal-title>
</journal-title-group>
<issn pub-type="epub">1932-6203</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, CA USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1371/journal.pone.0192243</article-id>
<article-id pub-id-type="publisher-id">PONE-D-17-32427</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
</subj-group>
<subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Neurology</subject><subj-group><subject>Neurodegenerative diseases</subject><subj-group><subject>Motor neuron diseases</subject><subj-group><subject>Amyotrophic lateral sclerosis</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and analysis methods</subject><subj-group><subject>Mathematical and statistical techniques</subject><subj-group><subject>Statistical methods</subject><subj-group><subject>Meta-analysis</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical sciences</subject><subj-group><subject>Mathematics</subject><subj-group><subject>Statistics (mathematics)</subject><subj-group><subject>Statistical methods</subject><subj-group><subject>Meta-analysis</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Science policy</subject><subj-group><subject>Research integrity</subject><subj-group><subject>Publication ethics</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Surgical and invasive medical procedures</subject><subj-group><subject>Endoscopy</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Nutrition</subject></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Nutrition</subject></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Otorhinolaryngology</subject><subj-group><subject>Laryngology</subject><subj-group><subject>Dysphagia</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Nutrition</subject><subj-group><subject>Malnutrition</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Nutrition</subject><subj-group><subject>Malnutrition</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Radiology and imaging</subject></subj-group></subj-group></article-categories>
<title-group>
<article-title>Therapeutic effects of percutaneous endoscopic gastrostomy on survival in patients with amyotrophic lateral sclerosis: A meta-analysis</article-title>
<alt-title alt-title-type="running-head">PEG in ALS patients</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Cui</surname>
<given-names>Fang</given-names>
</name>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Funding acquisition</role>
<role content-type="http://credit.casrai.org/">Visualization</role>
<role content-type="http://credit.casrai.org/">Writing – original draft</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Sun</surname>
<given-names>Liuqing</given-names>
</name>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Xiong</surname>
<given-names>Jianmei</given-names>
</name>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Li</surname>
<given-names>Jianyong</given-names>
</name>
<role content-type="http://credit.casrai.org/">Resources</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Zhao</surname>
<given-names>Yangang</given-names>
</name>
<role content-type="http://credit.casrai.org/">Software</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" corresp="yes" xlink:type="simple">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-9737-0512</contrib-id>
<name name-style="western">
<surname>Huang</surname>
<given-names>Xusheng</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Project administration</role>
<role content-type="http://credit.casrai.org/">Supervision</role>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
<xref ref-type="corresp" rid="cor001">*</xref>
</contrib>
</contrib-group>
<aff id="aff001"><label>1</label> <addr-line>Department of Neurology, Hainan Branch of Chinese PLA General Hospital, Sanya, Hainan, China</addr-line></aff>
<aff id="aff002"><label>2</label> <addr-line>Department of Neurology, Chinese PLA General Hospital, Beijing, China</addr-line></aff>
<contrib-group>
<contrib contrib-type="editor" xlink:type="simple">
<name name-style="western">
<surname>Green</surname>
<given-names>John</given-names>
</name>
<role>Editor</role>
<xref ref-type="aff" rid="edit1"/>
</contrib>
</contrib-group>
<aff id="edit1"><addr-line>University Hospital Llandough, UNITED KINGDOM</addr-line></aff>
<author-notes>
<fn fn-type="conflict" id="coi001">
<p>The authors have declared that no competing interests exist.</p>
</fn>
<corresp id="cor001">* E-mail: <email xlink:type="simple">lewish301@sina.com</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>6</day>
<month>2</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="collection">
<year>2018</year>
</pub-date>
<volume>13</volume>
<issue>2</issue>
<elocation-id>e0192243</elocation-id>
<history>
<date date-type="received">
<day>7</day>
<month>9</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>18</day>
<month>1</month>
<year>2018</year>
</date>
</history>
<permissions>
<copyright-year>2018</copyright-year>
<copyright-holder>Cui et al</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="info:doi/10.1371/journal.pone.0192243"/>
<abstract>
<p>Percutaneous endoscopic gastrostomy (PEG) is a method widely used for patients with amyotrophic lateral sclerosis (ALS); nevertheless, its effect on survival remains unclear. The purpose of this meta-analysis study was to determine the effects of PEG on survival in ALS patients. Relevant studies were retrieved from PubMed, EmBase, and the Cochrane Library databases, from inception to June 2017. Studies comparing PEG with other procedures in ALS patients were included. Odds ratios (ORs) in a random-effects model were used to assess the survival at different follow-up periods. Briefly, ten studies involving a total of 996 ALS patients were included. Summary ORs indicated that PEG administration was not associated with 30-day (OR = 1.59; 95%CI 0.93–2.71; P = 0.092), 10-month (OR = 1.25; 95%CI 0.72–2.17; P = 0.436), and 30-month (OR = 1.28; 95% CI 0.77–2.11; P = 0.338) survival rates, while they showed a beneficial effect in 20-month survival rate (OR = 1.97; 95%CI 1.21–3.21; P = 0.007). The survival rate was significantly prominent in reports published before 2005, and in studies with a retrospective design, sample size &lt;100, mean age &lt;60.0 years, and percentage male ≥50.0%. To sum up, these findings suggested that ALS patients administered with PEG had an increased 20-month survival rates, while there was no significant effect in 30-day, 10-month, and 30-month survival rates.</p>
</abstract>
<funding-group>
<award-group id="award001">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100001809</institution-id>
<institution>National Natural Science Foundation of China</institution>
</institution-wrap>
</funding-source>
<award-id>81601096</award-id>
</award-group>
<award-group id="award002">
<funding-source>
<institution>Key Research &amp; Developement Plan of Hainan Province</institution>
</funding-source>
<award-id>ZDYF2016120</award-id>
</award-group>
<funding-statement>This study was supported by the National Natural Science Foundation of China (Grant number 81601096) (<ext-link ext-link-type="uri" xlink:href="http://www.nsfc.gov.cn/" xlink:type="simple">http://www.nsfc.gov.cn/</ext-link>); Key Research &amp; Developement Plan of Hainan Province (Grant number ZDYF2016120) (<ext-link ext-link-type="uri" xlink:href="http://dost.hainan.gov.cn/" xlink:type="simple">http://dost.hainan.gov.cn/</ext-link>).</funding-statement>
</funding-group>
<counts>
<fig-count count="5"/>
<table-count count="4"/>
<page-count count="13"/>
</counts>
<custom-meta-group>
<custom-meta id="data-availability">
<meta-name>Data Availability</meta-name>
<meta-value>All relevant data are within the paper and its Supporting Information files.</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="sec001" sec-type="intro">
<title>Introduction</title>
<p>Amyotrophic lateral sclerosis (ALS) is a progressive degeneration of motor neurons, involving the upper and lower motor neurons of the spinal cord, brainstem, and cerebral cortex, that causes disability and death within three to five years following diagnosis [<xref ref-type="bibr" rid="pone.0192243.ref001">1</xref>–<xref ref-type="bibr" rid="pone.0192243.ref003">3</xref>]. ALS is cartherized by stiff muscles and muscle twitching, which in the majority of cases causes a progressive weakness and wasting of muscles which control the movement, breathing, and swallowing [<xref ref-type="bibr" rid="pone.0192243.ref004">4</xref>]. Malnutrition has been associated with a linear decline in muscle strength which increases the risk of death in patients with ALS [<xref ref-type="bibr" rid="pone.0192243.ref005">5</xref>–<xref ref-type="bibr" rid="pone.0192243.ref007">7</xref>]. Specifically, ALS patients with severe malnutrition suffer from muscle atrophy, muscle weakness, and diaphragmatic paralysis [<xref ref-type="bibr" rid="pone.0192243.ref008">8</xref>, <xref ref-type="bibr" rid="pone.0192243.ref009">9</xref>]. Therefore, effective nutritional care is particularly important in ALS patients.</p>
<p>Currently, gastrostomy that has shown to improve the disease prognosis, is widely used in ALS patients [<xref ref-type="bibr" rid="pone.0192243.ref010">10</xref>, <xref ref-type="bibr" rid="pone.0192243.ref011">11</xref>]. Two commonly used approaches for percutaneous gastrostomy are radiologic and endoscopic methods [<xref ref-type="bibr" rid="pone.0192243.ref012">12</xref>]. According to the American Academy of Neurology, ALS Practice Parameter guidelines, ALS patients with symptomatic dysphagia and vital capacity exceeding 50% of the predicted value should undergo percutaneous endoscopic gastrostomy (PEG). Nevertheless, only 13% of patients are administered with PEG due to lack of sufficient evidence for the effectiveness of PEG in ALS patients [<xref ref-type="bibr" rid="pone.0192243.ref013">13</xref>]. A previous meta-analysis demonstrated undefined effects of PEG on survival due to limited evidence, while PEG tubes have been associated with prolonged life in older individuals [<xref ref-type="bibr" rid="pone.0192243.ref014">14</xref>]. However, there was limited evidence demonstrating that PEG prolongs the survival in ALS patients [<xref ref-type="bibr" rid="pone.0192243.ref004">4</xref>]. Although numerous studies have evaluated the therapeutic effects of PEG on survival in ALS patients, supportive high-quality clinical evidence is not available. Hence, a more robust analysis of all the available studies is highly necessary. Here, we attempted a large-scale examination of the available studies comparing PEG and other procedures with regard to the survival in ALS patients.</p>
</sec>
<sec id="sec002" sec-type="materials|methods">
<title>Materials and methods</title>
<sec id="sec003">
<title>Data sources, search strategy, and selection criteria</title>
<p>This review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Statement guidelines issued in 2009 (<xref ref-type="supplementary-material" rid="pone.0192243.s001">S1 Checklist</xref>) [<xref ref-type="bibr" rid="pone.0192243.ref015">15</xref>]. The PubMed, EmBase, and Cochrane library were searched for articles assessing the effectiveness of PEG in ALS patients from the inception date to June 2017. The keywords used were the following: “(percutaneous endoscopic gastrostomy or PEG)” and “amyotrophic lateral sclerosis” or “sclerosis, amyotrophic lateral” or “Charcot disease” or “motor neuron disease”. The detailed search strategy in PubMed was presented in <bold><xref ref-type="supplementary-material" rid="pone.0192243.s002">S1 File</xref></bold>. The search was limited to the articles published in English language. The abstracts and virtual meeting presentations were searched to identify for relevant unpublished studies. We also hand-searched the journals for published relevant data, as well as the reference lists of all the retrieved articles and relevant review articles.</p>
<p>The literature search was independently undertaken by two investigators using a standardized approach, while any inconsistencies were settled by the primary author. The inclusion criteria were: (1) study with prospective or retrospective design; (2) all included patients had ALS; (3) patients administered either with PEG or non-PEG interventions; (4) availability of survival rate in each group. Studies were excluded if: (1) patients were diagnosed with other diseases; (2) the study with inappropriate control; and (3) studies without adequate data.</p>
</sec>
<sec id="sec004">
<title>Data collection and quality assessment</title>
<p>Data extraction and assessment were conducted independently by two investigators. Publication data (first author’s name and publication year), study characteristics (country, study design, sample size, mean age, percentage male, intervention, and control), and survival rates at different follow-up durations were extracted. Disagreements were resolved by a third reviewer or consensus-based discussion. 30-day survival rate was the primary endpoint in the present meta-analysis study, while the secondary endpoints included 10-month, 20-month, and 30-month survival rates.</p>
<p>The Newcastle-Ottawa Scale (NOS), which is quite comprehensive and has been partially validated for evaluating the quality of observational studies in the meta-analysis, was used to assess the methodological quality [<xref ref-type="bibr" rid="pone.0192243.ref016">16</xref>]. NOS were based on the following 3 subscales: selection (4 items), comparability (1 item), and outcome (3 items). A “star system” (range, 0–9) was developed for assessment. The quality assessment was performed independently by two investigators. The data were examined and adjudicated independently by an additional investigator based on original reports.</p>
</sec>
<sec id="sec005">
<title>Statistical analysis</title>
<p>The therapeutic effects of PEG on survival were assessed based on the number of surviving patients and sample size in each group for every study. Odds ratios (ORs) with corresponding 95% confidence intervals (CIs) were employed as summary statistics with random-effects model. The results from the random-effects model imply that the true underlying effect varies across the included studies [<xref ref-type="bibr" rid="pone.0192243.ref017">17</xref>, <xref ref-type="bibr" rid="pone.0192243.ref018">18</xref>]. Study heterogeneity was analyzed by Q statistics, with P&lt;0.10 denoting statistical significance. The degree of heterogeneity was based on the I<sup>2</sup> statistics, with I<sup>2</sup>&gt;50% indicating significant heterogeneity and data with I<sup>2</sup>&gt;75% were not included in the final analysis [<xref ref-type="bibr" rid="pone.0192243.ref019">19</xref>, <xref ref-type="bibr" rid="pone.0192243.ref020">20</xref>]. Sensitivity analysis was carried out by removing each individual study from the overall analysis to evaluate its influence on the obtained results [<xref ref-type="bibr" rid="pone.0192243.ref021">21</xref>]. Subgroup analyses were also conducted based on publication year, study design, sample size, mean age, and percentage of males. Furthermore, Chi-square test and meta-regression were used to assess various subgroups [<xref ref-type="bibr" rid="pone.0192243.ref022">22</xref>]. The Egger’s [<xref ref-type="bibr" rid="pone.0192243.ref023">23</xref>] and Begg’s [<xref ref-type="bibr" rid="pone.0192243.ref024">24</xref>] tests were used to statistically assess publication bias for major cardiovascular outcomes. Two-sided P&lt;0.05 was considered statistically significant. Statistical analyses were performed with the STATA software (version 12.0; Stata Corporation, College Station, TX, USA).</p>
</sec>
</sec>
<sec id="sec006" sec-type="results">
<title>Results</title>
<p>The study-selection process is shown in <bold><xref ref-type="fig" rid="pone.0192243.g001">Fig 1</xref></bold>. A total of 528 articles (187 from PubMed, 326 from EmBase, and 15 from Cochrane library) were retrieved during the initial electronic search, while 496 articles were irrelevant or duplicate, and thus were excluded. Meanwhile, 32 potentially eligible studies were selected. After detailed evaluation, 10 studies were selected for the final meta-analysis [<xref ref-type="bibr" rid="pone.0192243.ref010">10</xref>, <xref ref-type="bibr" rid="pone.0192243.ref025">25</xref>–<xref ref-type="bibr" rid="pone.0192243.ref033">33</xref>]. Twenty-two studies were excluded due to the following reasons: survival rate data was not reported in 17 studies; three studies included patients with other interventions; and 2 studies reported sample patient population. A manual search of the reference lists of the latter studies yielded no further eligible studies. General characteristics of the included studies are presented in <bold><xref ref-type="table" rid="pone.0192243.t001">Table 1</xref></bold>.</p>
<fig id="pone.0192243.g001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0192243.g001</object-id>
<label>Fig 1</label>
<caption>
<title>Flow diagram of the literature search and selection process.</title>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0192243.g001" xlink:type="simple"/>
</fig>
<table-wrap id="pone.0192243.t001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0192243.t001</object-id>
<label>Table 1</label> <caption><title>Baseline characteristic of studies included in the systematic review and meta-analysis.</title></caption>
<alternatives>
<graphic id="pone.0192243.t001g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0192243.t001" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="left">Study</th>
<th align="center">Country</th>
<th align="center">Study design</th>
<th align="center">Sample size</th>
<th align="center">Age</th>
<th align="center">Percentage of males(%)</th>
<th align="center">Intervention</th>
<th align="center">Control</th>
<th align="center">NOS score</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left">Shaw 2006 [<xref ref-type="bibr" rid="pone.0192243.ref025">25</xref>]</td>
<td align="center">UK</td>
<td align="center">Retrospective</td>
<td align="center">98</td>
<td align="center">61.0</td>
<td align="center">50.0</td>
<td align="center">PEG</td>
<td align="center">RIG or NG</td>
<td align="center">7</td>
</tr>
<tr>
<td align="left">Mathus-Vliegen 1994 [<xref ref-type="bibr" rid="pone.0192243.ref026">26</xref>]</td>
<td align="center">The Netherlands</td>
<td align="center">Prospective</td>
<td align="center">68</td>
<td align="center">57.0</td>
<td align="center">48.5</td>
<td align="center">PEG</td>
<td align="center">Other</td>
<td align="center">7</td>
</tr>
<tr>
<td align="left">Mazzini 1995 [<xref ref-type="bibr" rid="pone.0192243.ref010">10</xref>]</td>
<td align="center">Italy</td>
<td align="center">Prospective</td>
<td align="center">66</td>
<td align="center">59.9</td>
<td align="center">51.5</td>
<td align="center">PEG</td>
<td align="center">Other</td>
<td align="center">7</td>
</tr>
<tr>
<td align="left">Spataro 2011 [<xref ref-type="bibr" rid="pone.0192243.ref027">27</xref>]</td>
<td align="center">Italy</td>
<td align="center">Retrospective</td>
<td align="center">150</td>
<td align="center">60.5</td>
<td align="center">55.3</td>
<td align="center">PEG</td>
<td align="center">Other</td>
<td align="center">8</td>
</tr>
<tr>
<td align="left">Blondet 2010 [<xref ref-type="bibr" rid="pone.0192243.ref028">28</xref>]</td>
<td align="center">France</td>
<td align="center">Retrospective</td>
<td align="center">40</td>
<td align="center">66.1</td>
<td align="center">42.5</td>
<td align="center">PEG</td>
<td align="center">PRG</td>
<td align="center">7</td>
</tr>
<tr>
<td align="left">Thornton 2002 [<xref ref-type="bibr" rid="pone.0192243.ref029">29</xref>]</td>
<td align="center">Ireland</td>
<td align="center">Retrospective</td>
<td align="center">36</td>
<td align="center">54.0</td>
<td align="center">52.8</td>
<td align="center">PEG</td>
<td align="center">PRG</td>
<td align="center">7</td>
</tr>
<tr>
<td align="left">Allen 2013 [<xref ref-type="bibr" rid="pone.0192243.ref030">30</xref>]</td>
<td align="center">USA</td>
<td align="center">Retrospective</td>
<td align="center">108</td>
<td align="center">60.6</td>
<td align="center">59.3</td>
<td align="center">PEG</td>
<td align="center">RIG</td>
<td align="center">8</td>
</tr>
<tr>
<td align="left">Desport 2005 [<xref ref-type="bibr" rid="pone.0192243.ref031">31</xref>]</td>
<td align="center">France</td>
<td align="center">Prospective</td>
<td align="center">50</td>
<td align="center">65.9</td>
<td align="center">52.0</td>
<td align="center">PEG</td>
<td align="center">RIG</td>
<td align="center">7</td>
</tr>
<tr>
<td align="left">ProGas Study Group 2015 [<xref ref-type="bibr" rid="pone.0192243.ref032">32</xref>]</td>
<td align="center">UK</td>
<td align="center">Prospective</td>
<td align="center">330</td>
<td align="center">64.4</td>
<td align="center">55.0</td>
<td align="center">PEG</td>
<td align="center">RIG or PIG</td>
<td align="center">8</td>
</tr>
<tr>
<td align="left">Chio 2004 [<xref ref-type="bibr" rid="pone.0192243.ref033">33</xref>]</td>
<td align="center">Italy</td>
<td align="center">Retrospective</td>
<td align="center">50</td>
<td align="center">67.0</td>
<td align="center">50.0</td>
<td align="center">PEG</td>
<td align="center">PRG</td>
<td align="center">7</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t001fn001"><p>*PEG, percutaneous endoscopic gastrostomy; RIG, radiological inserted gastrostomy; NG, nasogastric tube; PRG, percutaneous radiologic gastrostomy; PIG, per-oral image-guided gastrostomy; NOS, Newcastle-Ottawa Scale</p></fn>
</table-wrap-foot>
</table-wrap>
<p>Among 10 included studies (including a total of 996 ALS patients), 4 [<xref ref-type="bibr" rid="pone.0192243.ref010">10</xref>, <xref ref-type="bibr" rid="pone.0192243.ref025">25</xref>–<xref ref-type="bibr" rid="pone.0192243.ref033">33</xref>] were prospective studies and 6 were retrospective trials. The mean age of ALS patients was 54.0–67.0 years, and 36–330 patients were included in each study. Two studies were conducted in UK [<xref ref-type="bibr" rid="pone.0192243.ref025">25</xref>, <xref ref-type="bibr" rid="pone.0192243.ref032">32</xref>], 3 in Italy [<xref ref-type="bibr" rid="pone.0192243.ref010">10</xref>, <xref ref-type="bibr" rid="pone.0192243.ref027">27</xref>, <xref ref-type="bibr" rid="pone.0192243.ref033">33</xref>], 2 in France [<xref ref-type="bibr" rid="pone.0192243.ref028">28</xref>, <xref ref-type="bibr" rid="pone.0192243.ref031">31</xref>], 1 in the Netherlands [<xref ref-type="bibr" rid="pone.0192243.ref026">26</xref>], 1 in Ireland [<xref ref-type="bibr" rid="pone.0192243.ref029">29</xref>], and 1 in USA [<xref ref-type="bibr" rid="pone.0192243.ref030">30</xref>]. Study quality was evaluated using the NOS scale. Three studies had a score of 8 [<xref ref-type="bibr" rid="pone.0192243.ref027">27</xref>, <xref ref-type="bibr" rid="pone.0192243.ref030">30</xref>, <xref ref-type="bibr" rid="pone.0192243.ref032">32</xref>], while 7 had a score of 7 [<xref ref-type="bibr" rid="pone.0192243.ref010">10</xref>, <xref ref-type="bibr" rid="pone.0192243.ref025">25</xref>, <xref ref-type="bibr" rid="pone.0192243.ref026">26</xref>, <xref ref-type="bibr" rid="pone.0192243.ref028">28</xref>, <xref ref-type="bibr" rid="pone.0192243.ref029">29</xref>, <xref ref-type="bibr" rid="pone.0192243.ref031">31</xref>, <xref ref-type="bibr" rid="pone.0192243.ref033">33</xref>], respectively.</p>
<p>The effects of PEG on 30-day survival rate in ALS patients was reported in ten studies. The summary OR indicated that PEG administration in ALS patients was not associated with 30-day survival rate (OR = 1.59; 95%CI 0.93–2.71; P = 0.092; <bold><xref ref-type="fig" rid="pone.0192243.g002">Fig 2</xref></bold>), and with no overt heterogeneity (I<sup>2</sup> = 0.0%; P = 0.966). Sensitivity analysis was performed, and sequential removal of each study from the pooled analysis did not significantly affect the overall results of the meta-analysis (<bold><xref ref-type="table" rid="pone.0192243.t002">Table 2</xref></bold>). Furthermore, subgroup analysis data were consistent with the overall findings, and no pre-defined factors affected the therapeutic effects of PEG on 30-day survival rate (<bold><xref ref-type="table" rid="pone.0192243.t003">Table 3</xref></bold>). In addition, sample size, mean age, and gender were not considered as significant factors on 30-day survival rate (<bold><xref ref-type="supplementary-material" rid="pone.0192243.s003">S1 Table</xref></bold>). Finally, there was no significant publication bias among the included studies (P value for the Egger’s test, 0.402; P value for the Begg’s test, 0.754; <bold><xref ref-type="table" rid="pone.0192243.t004">Table 4</xref></bold>).</p>
<fig id="pone.0192243.g002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0192243.g002</object-id>
<label>Fig 2</label>
<caption>
<title>Association of PEG use with 30-day survival rate.</title>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0192243.g002" xlink:type="simple"/>
</fig>
<table-wrap id="pone.0192243.t002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0192243.t002</object-id>
<label>Table 2</label> <caption><title>Sensitivity analysis.</title></caption>
<alternatives>
<graphic id="pone.0192243.t002g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0192243.t002" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="left">Outcomes</th>
<th align="center">Excluding study</th>
<th align="center">OR and 95% CI</th>
<th align="center">P value</th>
<th align="center">Heterogeneity (%)</th>
<th align="center">P value for heterogeneity</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="10"><bold>30-day survival rate</bold></td>
<td align="center">Shaw 2006</td>
<td align="center">1.69 (0.95–3.03)</td>
<td align="center">0.076</td>
<td align="center">0.0</td>
<td align="center">0.955</td>
</tr>
<tr>
<td align="center">Mathus-Vliegen 1994</td>
<td align="center">1.49 (0.84–2.65)</td>
<td align="center">0.168</td>
<td align="center">0.0</td>
<td align="center">0.957</td>
</tr>
<tr>
<td align="center">Mazzini 1995</td>
<td align="center">1.58 (0.91–2.73)</td>
<td align="center">0.105</td>
<td align="center">0.0</td>
<td align="center">0.935</td>
</tr>
<tr>
<td align="center">Spataro 2011</td>
<td align="center">1.59 (0.93–2.71)</td>
<td align="center">0.092</td>
<td align="center">0.0</td>
<td align="center">0.966</td>
</tr>
<tr>
<td align="center">Blondet 2010</td>
<td align="center">1.65 (0.95–2.87)</td>
<td align="center">0.078</td>
<td align="center">0.0</td>
<td align="center">0.951</td>
</tr>
<tr>
<td align="center">Thornton 2002</td>
<td align="center">1.55 (0.89–2.68)</td>
<td align="center">0.120</td>
<td align="center">0.0</td>
<td align="center">0.947</td>
</tr>
<tr>
<td align="center">Allen 2013</td>
<td align="center">1.55 (0.86–2.79)</td>
<td align="center">0.141</td>
<td align="center">0.0</td>
<td align="center">0.937</td>
</tr>
<tr>
<td align="center">Desport 2005</td>
<td align="center">1.71 (0.98–3.00)</td>
<td align="center">0.060</td>
<td align="center">0.0</td>
<td align="center">0.979</td>
</tr>
<tr>
<td align="center">ProGas Study Group 2015</td>
<td align="center">1.41 (0.76–2.61)</td>
<td align="center">0.278</td>
<td align="center">0.0</td>
<td align="center">0.969</td>
</tr>
<tr>
<td align="center">Chio 2004</td>
<td align="center">1.64 (0.94–2.86)</td>
<td align="center">0.080</td>
<td align="center">0.0</td>
<td align="center">0.949</td>
</tr>
<tr>
<td align="left" rowspan="9"><bold>10-month survival rate</bold></td>
<td align="center">Shaw 2006</td>
<td align="center">1.25 (0.65–2.39)</td>
<td align="center">0.500</td>
<td align="center">55.5</td>
<td align="center">0.028</td>
</tr>
<tr>
<td align="center">Mathus-Vliegen 1994</td>
<td align="center">1.28 (0.69–2.39)</td>
<td align="center">0.434</td>
<td align="center">54.9</td>
<td align="center">0.030</td>
</tr>
<tr>
<td align="center">Mazzini 1995</td>
<td align="center">1.17 (0.61–2.24)</td>
<td align="center">0.641</td>
<td align="center">54.7</td>
<td align="center">0.031</td>
</tr>
<tr>
<td align="center">Spataro 2011</td>
<td align="center">1.25 (0.69–2.25)</td>
<td align="center">0.458</td>
<td align="center">55.5</td>
<td align="center">0.028</td>
</tr>
<tr>
<td align="center">Blondet 2010</td>
<td align="center">1.12 (0.62–2.02)</td>
<td align="center">0.709</td>
<td align="center">50.0</td>
<td align="center">0.051</td>
</tr>
<tr>
<td align="center">Thornton 2002</td>
<td align="center">1.09 (0.64–1.87)</td>
<td align="center">0.741</td>
<td align="center">41.8</td>
<td align="center">0.100</td>
</tr>
<tr>
<td align="center">Desport 2005</td>
<td align="center">1.44 (0.81–2.53)</td>
<td align="center">0.212</td>
<td align="center">44.6</td>
<td align="center">0.082</td>
</tr>
<tr>
<td align="center">ProGas Study Group 2015</td>
<td align="center">1.18 (0.56–2.51)</td>
<td align="center">0.660</td>
<td align="center">56.2</td>
<td align="center">0.025</td>
</tr>
<tr>
<td align="center">Chio 2004</td>
<td align="center">1.38 (0.91–2.10)</td>
<td align="center">0.125</td>
<td align="center">20.2</td>
<td align="center">0.269</td>
</tr>
<tr>
<td align="left" rowspan="7"><bold>20-month survival rate</bold></td>
<td align="center">Shaw 2006</td>
<td align="center">1.94 (1.16–3.26)</td>
<td align="center">0.012</td>
<td align="center">0.0</td>
<td align="center">0.490</td>
</tr>
<tr>
<td align="center">Mathus-Vliegen 1994</td>
<td align="center">2.04 (1.22–3.40)</td>
<td align="center">0.006</td>
<td align="center">0.0</td>
<td align="center">0.514</td>
</tr>
<tr>
<td align="center">Mazzini 1995</td>
<td align="center">1.68 (0.99–2.85)</td>
<td align="center">0.055</td>
<td align="center">0.0</td>
<td align="center">0.832</td>
</tr>
<tr>
<td align="center">Spataro 2011</td>
<td align="center">2.13 (1.16–3.92)</td>
<td align="center">0.015</td>
<td align="center">0.0</td>
<td align="center">0.510</td>
</tr>
<tr>
<td align="center">Blondet 2010</td>
<td align="center">1.86 (1.11–3.12)</td>
<td align="center">0.018</td>
<td align="center">0.0</td>
<td align="center">0.545</td>
</tr>
<tr>
<td align="center">Thornton 2002</td>
<td align="center">2.02 (1.20–3.39)</td>
<td align="center">0.008</td>
<td align="center">0.0</td>
<td align="center">0.497</td>
</tr>
<tr>
<td align="center">Desport 2005</td>
<td align="center">2.18 (1.31–3.62)</td>
<td align="center">0.003</td>
<td align="center">0.0</td>
<td align="center">0.762</td>
</tr>
<tr>
<td align="left" rowspan="6"><bold>30-month survival rate</bold></td>
<td align="center">Shaw 2006</td>
<td align="center">1.25 (0.74–2.10)</td>
<td align="center">0.409</td>
<td align="center">0.0</td>
<td align="center">0.928</td>
</tr>
<tr>
<td align="center">Mathus-Vliegen 1994</td>
<td align="center">1.28 (0.76–2.17)</td>
<td align="center">0.352</td>
<td align="center">0.0</td>
<td align="center">0.913</td>
</tr>
<tr>
<td align="center">Spataro 2011</td>
<td align="center">1.34 (0.61–2.97)</td>
<td align="center">0.463</td>
<td align="center">0.0</td>
<td align="center">0.917</td>
</tr>
<tr>
<td align="center">Blondet 2010</td>
<td align="center">1.22 (0.73–2.03)</td>
<td align="center">0.451</td>
<td align="center">0.0</td>
<td align="center">0.993</td>
</tr>
<tr>
<td align="center">Thornton 2002</td>
<td align="center">1.32 (0.77–2.23)</td>
<td align="center">0.310</td>
<td align="center">0.0</td>
<td align="center">0.929</td>
</tr>
<tr>
<td align="center">Desport 2005</td>
<td align="center">1.30 (0.77–2.18)</td>
<td align="center">0.320</td>
<td align="center">0.0</td>
<td align="center">0.923</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t002fn001"><p>*OR, odds ratio; CI, confidence interval</p></fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="pone.0192243.t003" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0192243.t003</object-id>
<label>Table 3</label> <caption><title>Subgroup analysis.</title></caption>
<alternatives>
<graphic id="pone.0192243.t003g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0192243.t003" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="left">Outcomes</th>
<th align="center">Group</th>
<th align="center">OR and 95%CI</th>
<th align="center">P value</th>
<th align="center">Heterogeneity (%)</th>
<th align="center">P value for heterogeneity</th>
<th align="center">P value for heterogeneity between subgroups</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="15"><bold>30-day survival rate</bold></td>
<td align="left" colspan="6">Publication year</td>
</tr>
<tr>
<td align="center">2005 or after</td>
<td align="center">1.48(0.78–2.78)</td>
<td align="center">0.228</td>
<td align="center">0.0</td>
<td align="center">0.798</td>
<td align="center" rowspan="2">0.674</td>
</tr>
<tr>
<td align="center">Before 2005</td>
<td align="center">1.91(0.70–5.22)</td>
<td align="center">0.210</td>
<td align="center">0.0</td>
<td align="center">0.905</td>
</tr>
<tr>
<td align="left" colspan="6">Study design</td>
</tr>
<tr>
<td align="left">Prospective</td>
<td align="center">1.86(0.87–3.96)</td>
<td align="center">0.108</td>
<td align="center">0.0</td>
<td align="center">0.723</td>
<td align="center" rowspan="2">0.562</td>
</tr>
<tr>
<td align="left">Retrospective</td>
<td align="center">1.35(0.63–2.89)</td>
<td align="center">0.436</td>
<td align="center">0.0</td>
<td align="center">0.947</td>
</tr>
<tr>
<td align="left" colspan="6">Sample size</td>
</tr>
<tr>
<td align="left">100 or larger</td>
<td align="center">2.06(0.89–4.77)</td>
<td align="center">0.090</td>
<td align="center">0.0</td>
<td align="center">0.767</td>
<td align="center" rowspan="2">0.424</td>
</tr>
<tr>
<td align="left">&lt; 100</td>
<td align="center">1.32(0.66–2.65)</td>
<td align="center">0.433</td>
<td align="center">0.0</td>
<td align="center">0.947</td>
</tr>
<tr>
<td align="left" colspan="6">Mean age (years)</td>
</tr>
<tr>
<td align="left">60 or older</td>
<td align="center">1.43(0.78–2.61)</td>
<td align="center">0.250</td>
<td align="center">0.0</td>
<td align="center">0.878</td>
<td align="center" rowspan="2">0.456</td>
</tr>
<tr>
<td align="left">&lt; 60</td>
<td align="center">2.34(0.74–7.46)</td>
<td align="center">0.149</td>
<td align="center">0.0</td>
<td align="center">0.972</td>
</tr>
<tr>
<td align="left" colspan="6">Percentage male (%)</td>
</tr>
<tr>
<td align="center">50 or larger</td>
<td align="center">1.55(0.86–2.81)</td>
<td align="center">0.147</td>
<td align="center">0.0</td>
<td align="center">0.933</td>
<td align="center" rowspan="2">0.877</td>
</tr>
<tr>
<td align="center">&lt;50</td>
<td align="center">1.74(0.51–5.99)</td>
<td align="center">0.378</td>
<td align="center">0.0</td>
<td align="center">0.469</td>
</tr>
<tr>
<td align="left" rowspan="15"><bold>10-month survival rate</bold></td>
<td align="left" colspan="6">Publication year</td>
</tr>
<tr>
<td align="center">2005 or after</td>
<td align="center">1.22(0.77–1.93)</td>
<td align="center">0.398</td>
<td align="center">14.4</td>
<td align="center">0.322</td>
<td align="center" rowspan="2">1.000</td>
</tr>
<tr>
<td align="center">Before 2005</td>
<td align="center">1.06(0.25–4.54)</td>
<td align="center">0.938</td>
<td align="center">74.3</td>
<td align="center">0.009</td>
</tr>
<tr>
<td align="left" colspan="6">Study design</td>
</tr>
<tr>
<td align="center">Prospective</td>
<td align="center">1.17(0.77–1.79)</td>
<td align="center">0.457</td>
<td align="center">10.6</td>
<td align="center">0.340</td>
<td align="center" rowspan="2">1.000</td>
</tr>
<tr>
<td align="center">Retrospective</td>
<td align="center">1.28(0.34–4.81)</td>
<td align="center">0.717</td>
<td align="center">68.3</td>
<td align="center">0.013</td>
</tr>
<tr>
<td align="left" colspan="6">Sample size</td>
</tr>
<tr>
<td align="center">100 or larger</td>
<td align="center">1.32(0.85–2.05)</td>
<td align="center">0.217</td>
<td align="center">0.0</td>
<td align="center">0.859</td>
<td align="center" rowspan="2">1.000</td>
</tr>
<tr>
<td align="center">&lt; 100</td>
<td align="center">1.18(0.53–2.65)</td>
<td align="center">0.685</td>
<td align="center">62.4</td>
<td align="center">0.014</td>
</tr>
<tr>
<td align="left" colspan="6">Mean age (years)</td>
</tr>
<tr>
<td align="center">60 or older</td>
<td align="center">0.96(0.45–2.05)</td>
<td align="center">0.919</td>
<td align="center">56.2</td>
<td align="center">0.044</td>
<td align="center" rowspan="2">0.256</td>
</tr>
<tr>
<td align="center">&lt; 60</td>
<td align="center">1.91(0.80–4.59)</td>
<td align="center">0.147</td>
<td align="center">34.8</td>
<td align="center">0.216</td>
</tr>
<tr>
<td align="left" colspan="6">Percentage male (%)</td>
</tr>
<tr>
<td align="center">50 or larger</td>
<td align="center">1.13(0.58–2.22)</td>
<td align="center">0.721</td>
<td align="center">56.6</td>
<td align="center">0.032</td>
<td align="center" rowspan="2">0.577</td>
</tr>
<tr>
<td align="center">&lt;50</td>
<td align="center">1.69(0.52–5.52)</td>
<td align="center">0.386</td>
<td align="center">38.5</td>
<td align="center">0.202</td>
</tr>
<tr>
<td align="left" rowspan="15"><bold>20-month survival rate</bold></td>
<td align="left" colspan="6">Publication year</td>
</tr>
<tr>
<td align="center">2005 or after</td>
<td align="center">1.74(0.95–3.18)</td>
<td align="center">0.074</td>
<td align="center">0.0</td>
<td align="center">0.562</td>
<td align="center" rowspan="2">0.492</td>
</tr>
<tr>
<td align="center">Before 2005</td>
<td align="center">2.49(1.09–5.68)</td>
<td align="center">0.031</td>
<td align="center">0.0</td>
<td align="center">0.381</td>
</tr>
<tr>
<td align="left" colspan="6">Study design</td>
</tr>
<tr>
<td align="center">Prospective</td>
<td align="center">1.81(0.53–6.18)</td>
<td align="center">0.344</td>
<td align="center">48.3</td>
<td align="center">0.145</td>
<td align="center" rowspan="2">0.929</td>
</tr>
<tr>
<td align="center">Retrospective</td>
<td align="center">1.94(1.07–3.50)</td>
<td align="center">0.028</td>
<td align="center">0.0</td>
<td align="center">0.902</td>
</tr>
<tr>
<td align="left" colspan="6">Sample size</td>
</tr>
<tr>
<td align="center">100 or larger</td>
<td align="center">1.71(0.76–3.87)</td>
<td align="center">0.194</td>
<td align="center">-</td>
<td align="center">-</td>
<td align="center" rowspan="2">0.677</td>
</tr>
<tr>
<td align="center">&lt; 100</td>
<td align="center">2.13(1.16–3.92)</td>
<td align="center">0.015</td>
<td align="center">0.0</td>
<td align="center">0.510</td>
</tr>
<tr>
<td align="left" colspan="6">Mean age (years)</td>
</tr>
<tr>
<td align="center">60 or older</td>
<td align="center">1.74(0.95–3.18)</td>
<td align="center">0.074</td>
<td align="center">0.0</td>
<td align="center">0.562</td>
<td align="center" rowspan="2">0.492</td>
</tr>
<tr>
<td align="center">&lt; 60</td>
<td align="center">2.49(1.09–5.68)</td>
<td align="center">0.031</td>
<td align="center">0.0</td>
<td align="center">0.381</td>
</tr>
<tr>
<td align="left" colspan="6">Percentage male (%)</td>
</tr>
<tr>
<td align="center">50 or larger</td>
<td align="center">1.93(1.12–3.31)</td>
<td align="center">0.018</td>
<td align="center">0.0</td>
<td align="center">0.422</td>
<td align="center" rowspan="2">0.859</td>
</tr>
<tr>
<td align="center">&lt;50</td>
<td align="center">2.16(0.71–6.58)</td>
<td align="center">0.177</td>
<td align="center">0.0</td>
<td align="center">0.465</td>
</tr>
<tr>
<td align="left" rowspan="15"><bold>30-month survival rate</bold></td>
<td align="left" colspan="6">Publication year</td>
</tr>
<tr>
<td align="center">2005 or after</td>
<td align="center">1.33(0.76–2.32)</td>
<td align="center">0.321</td>
<td align="center">0.0</td>
<td align="center">0.835</td>
<td align="center" rowspan="2">0.765</td>
</tr>
<tr>
<td align="center">Before 2005</td>
<td align="center">1.10(0.36–3.36)</td>
<td align="center">0.872</td>
<td align="center">0.0</td>
<td align="center">0.861</td>
</tr>
<tr>
<td align="left" colspan="6">Study design</td>
</tr>
<tr>
<td align="center">Prospective</td>
<td align="center">1.12(0.32–3.89)</td>
<td align="center">0.858</td>
<td align="center">0.0</td>
<td align="center">0.875</td>
<td align="center" rowspan="2">0.822</td>
</tr>
<tr>
<td align="center">Retrospective</td>
<td align="center">1.31(0.76–2.26)</td>
<td align="center">0.333</td>
<td align="center">0.0</td>
<td align="center">0.824</td>
</tr>
<tr>
<td align="left" colspan="6">Sample size</td>
</tr>
<tr>
<td align="center">100 or larger</td>
<td align="center">1.23(0.65–2.35)</td>
<td align="center">0.523</td>
<td align="center">-</td>
<td align="center">-</td>
<td align="center" rowspan="2">0.870</td>
</tr>
<tr>
<td align="center">&lt; 100</td>
<td align="center">1.34(0.61–2.97)</td>
<td align="center">0.463</td>
<td align="center">0.0</td>
<td align="center">0.917</td>
</tr>
<tr>
<td align="left" colspan="6">Mean age (years)</td>
</tr>
<tr>
<td align="center">60 or older</td>
<td align="center">1.33(0.76–2.32)</td>
<td align="center">0.321</td>
<td align="center">0.0</td>
<td align="center">0.835</td>
<td align="center" rowspan="2">0.765</td>
</tr>
<tr>
<td align="center">&lt; 60</td>
<td align="center">1.10(0.36–3.36)</td>
<td align="center">0.872</td>
<td align="center">0.0</td>
<td align="center">0.861</td>
</tr>
<tr>
<td align="left" colspan="6">Percentage male (%)</td>
</tr>
<tr>
<td align="center">50 or larger</td>
<td align="center">1.22(0.71–2.08)</td>
<td align="center">0.474</td>
<td align="center">0.0</td>
<td align="center">0.971</td>
<td align="center" rowspan="2">0.635</td>
</tr>
<tr>
<td align="center">&lt;50</td>
<td align="center">1.73(0.45–6.70)</td>
<td align="center">0.426</td>
<td align="center">0.0</td>
<td align="center">0.473</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t003fn001"><p>*OR, odds ratio; CI, confidence interval</p></fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="pone.0192243.t004" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0192243.t004</object-id>
<label>Table 4</label> <caption><title>Publication bias analysis.</title></caption>
<alternatives>
<graphic id="pone.0192243.t004g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0192243.t004" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="left">Outcomes</th>
<th align="center">P value for the Egger’s test</th>
<th align="center">P value for the Begg’s test</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left"><bold>30-day survival rate</bold></td>
<td align="center">0.402</td>
<td align="center">0.754</td>
</tr>
<tr>
<td align="left"><bold>10-month survival rate</bold></td>
<td align="center">0.546</td>
<td align="center">0.754</td>
</tr>
<tr>
<td align="left"><bold>20-month survival rate</bold></td>
<td align="center">0.816</td>
<td align="center">0.368</td>
</tr>
<tr>
<td align="left"><bold>30-month survival rate</bold></td>
<td align="center">0.460</td>
<td align="center">0.260</td>
</tr>
</tbody>
</table>
</alternatives>
</table-wrap>
<p>A total of 9 studies evaluated the effects of PEG on 10-month survival rate in ALS patients. Our results showed no significant association between PEG and 10-month survival rate (OR = 1.25; 95%CI 0.72–2.17; P = 0.436; <xref ref-type="fig" rid="pone.0192243.g003">Fig 3</xref>). Although substantial heterogeneity was observed in the magnitude of effects across studies (I<sup>2</sup> = 49.3%; P = 0.046), sequential exclusion of each study from the pooled data did not affect the overall results (<bold><xref ref-type="table" rid="pone.0192243.t002">Table 2</xref></bold>). Furthermore, meta-regression analyses suggested that sample size, mean age, and gender (percentage of male patients) did not affect the 10-month survival rate (<bold><xref ref-type="supplementary-material" rid="pone.0192243.s003">S1 Table</xref></bold>). Findings of subgroup analysis were consistent with the overall analysis (<bold><xref ref-type="table" rid="pone.0192243.t003">Table 3</xref></bold>) and no publication bias was observed (P value for the Egger’s test, 0.546; P value for the Begg’s test, 0.754; <bold><xref ref-type="table" rid="pone.0192243.t004">Table 4</xref></bold>).</p>
<fig id="pone.0192243.g003" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0192243.g003</object-id>
<label>Fig 3</label>
<caption>
<title>Association of PEG use with 10-month survival rate.</title>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0192243.g003" xlink:type="simple"/>
</fig>
<p>A total of 7 studies assessed the effects of PEG on 20-month survival rate in ALS patients. Pooled analysis of 20-month survival rate indicated a beneficial effect of PEG compared with other procedures (OR = 1.97; 95%CI 1.21–3.21; P = 0.007; <bold><xref ref-type="fig" rid="pone.0192243.g004">Fig 4</xref></bold>). There was no significant heterogeneity among the included studies (I<sup>2</sup> = 0.0%; P = 0.616). Sequential exclusion of each study from the pooled data did not affect the overall conclusion (<bold><xref ref-type="table" rid="pone.0192243.t002">Table 2</xref></bold>). The results of meta-regression analyses found that sample size, mean age, and gender (percentage of male patients) were not correlated with 20-month survival rate (<bold><xref ref-type="supplementary-material" rid="pone.0192243.s003">S1 Table</xref></bold>). Subgroup analysis suggested significant improvement in 20-month survival rate, which was prominent in studies published before 2005, and those with a retrospective design, sample size &lt;100, mean age &lt;60.0 years, and percentage of male patients ≥50.0% (<xref ref-type="table" rid="pone.0192243.t003">Table 3</xref>). Egger’s (P = 0.816) and Begg’s (P = 0.368) tests suggested no significant publication bias for 20-month survival rate (<bold><xref ref-type="table" rid="pone.0192243.t004">Table 4</xref></bold>).</p>
<fig id="pone.0192243.g004" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0192243.g004</object-id>
<label>Fig 4</label>
<caption>
<title>Association of PEG use and 20-month survival rate.</title>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0192243.g004" xlink:type="simple"/>
</fig>
<p>A total of 6 studies reported the effects of PEG on 30-month survival rate in ALS patients. Pooled analysis indicated that there was no association between PEG and 30-month survival rate (OR = 1.28; 95%CI 0.77–2.11; P = 0.338; <bold><xref ref-type="fig" rid="pone.0192243.g005">Fig 5</xref></bold>). Although no heterogeneity was detected across the included studies (I<sup>2</sup> = 0.0%; P = 0.964), sensitivity analysis was conducted. After sequential exclusion of each study from the pooled analysis, the conclusion was not affected (<bold><xref ref-type="table" rid="pone.0192243.t002">Table 2</xref></bold>). Sample size, mean age, and gender (percentage of male patients) did not significantly affect the 30-month survival rate (<bold><xref ref-type="supplementary-material" rid="pone.0192243.s003">S1 Table</xref></bold>). There were no significant differences in 30-month survival rate based on subgroup analysis (<bold><xref ref-type="table" rid="pone.0192243.t003">Table 3</xref></bold>). No significant publication bias was observed among the included studies (P value for the Egger’s test was 0.460; P value for the Begg’s test was 0.260; <bold><xref ref-type="table" rid="pone.0192243.t004">Table 4</xref></bold>).</p>
<fig id="pone.0192243.g005" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0192243.g005</object-id>
<label>Fig 5</label>
<caption>
<title>Association of PEG use and 30-month survival rate.</title>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0192243.g005" xlink:type="simple"/>
</fig>
</sec>
<sec id="sec007" sec-type="conclusions">
<title>Discussion</title>
<p>The current meta-analysis explored the therapeutic effects of PEG and survival rates at different follow-up durations based on a total of 996 ALS patients with a broad range of ethnicities assessed in 4 prospective and 6 retrospective studies. The obtained results suggested that compared to control, PEG had no effect on 30-day, 10-month, and 30-month survival rates. Yet, PEG showed a significant increase in 20-month survival rates. Sensitivity and subgroup analysis findings were consistent with the overall analysis for 30-day, 10-month, and 30-month survival rates. The therapeutic effects of PEG on 20-month survival rate were outstanding in studies published before 2005, and in studies with a retrospective design, sample size &lt;100, mean age &lt;60.0 years, and percentage of male patients ≥ 50.0%.</p>
<p>Malnutrition is an independent prognostic factor for muscle weakness and death in patients with ALS. Both dysphagia and hypermetabolism are significant risk factors for malnutrition, and they remain to be a major problem in ALS patients [<xref ref-type="bibr" rid="pone.0192243.ref034">34</xref>–<xref ref-type="bibr" rid="pone.0192243.ref036">36</xref>]. Currently, enteral nutrition is widely used to treat dysphagia in ALS patients. Therefore, ALS patients with dysphagia undergo PEG as a routine procedure for nutrition improvement, although the effects of PEG on survival remain undefined. Shaw et al [<xref ref-type="bibr" rid="pone.0192243.ref025">25</xref>] have reported equivalent post-procedure survival rates between PEG and radiological inserted gastrostomy, which have been found to decrease the morbidity and mortality. Finally, poor survival rate was expectedly observed in the nasogastric tube group, even though most of the patients who participated in the study were in pre-terminal stages of ALS. Mathus-Vliegen et al [<xref ref-type="bibr" rid="pone.0192243.ref026">26</xref>] have suggested PEG is a successful and safe procedure in highly disabled ALS patients with respiratory compromise and far-advanced neurologic disease. Mazzini et al [<xref ref-type="bibr" rid="pone.0192243.ref010">10</xref>] have indicated that long-term PEG use is associated with significantly improved survival rate in ALS patients with bulbar involvement. The possible reason for this is that most ALS patients die at home due to broncho-pneumonic complications, while PEG is associated with low incidence of pneumonia and cachexia. Spataro et al [<xref ref-type="bibr" rid="pone.0192243.ref027">27</xref>] have retrospectively analyzed 150 ALS patients with dysphagia, and found that PEG significantly improved survival, with fewer side effects. Furthermore, another study has also suggested that patients with spinal-onset benefitted more compared to their bulbar-onset counterparts. Blondet et al [<xref ref-type="bibr" rid="pone.0192243.ref028">28</xref>] have suggested that percutaneous radiologic gastrostomy is more efficacious and well-tolerated compared to PEG in ALS patients, likely because PEG has been associated with an increased risk of respiratory decompensation in ALS patients. Thornton et al [<xref ref-type="bibr" rid="pone.0192243.ref029">29</xref>] have demonstrated that percutaneous radiologic gastrostomy is associated with increased success rate compared with PEG. Allen et al [<xref ref-type="bibr" rid="pone.0192243.ref030">30</xref>] have indicated that PEG significantly increased the risk of post-procedure aspiration, while no significant difference has been observed in 30-day survival rate between the PEG and radiologic gastrostomy groups. Desport et al [<xref ref-type="bibr" rid="pone.0192243.ref031">31</xref>] have found no significant difference between PEG and RIG in survival rates, revealing a higher failure rate in the PEG group compared to RIG group. A study by ProGas Study Group indicated no significant difference in the survival rate and adverse events among PEG, radiologically inserted gastrostomy, and per-oral image-guided gastrostomy [<xref ref-type="bibr" rid="pone.0192243.ref032">32</xref>]. Chio et al have demonstrated that percutaneous radiological gastrostomy is superior to PEG in terms of survival in ALS patients with moderate or severe respiratory impairment [<xref ref-type="bibr" rid="pone.0192243.ref033">33</xref>]. They also proposed the use of nasogastric tube in the percutaneous radiological gastrostomy procedures, which is considered more favorable in patients with masseter spasm as they cannot open the mouth. The important strengths of the present study involve comprehensive inclusion of relevant studies with larger statistical power compared with any individual study. In addition, this report was based on 10 studies that were conducted in different countries, and that have broad characteristics, suggesting the broad applicability of the present findings.</p>
<p>The present meta-analysis suggested that ALS patients receiving PEG were associated with higher incidence of 20-month survival, while no significant differences were observed for 30-day, 10-month, and 30-month survival rates. However, due to chance these results might not be enough to substantiate a causal relationship between the impact of PEG on survival rate at different follow-up durations. The possible reason for this could be that the pooled results were obtained from various included studies. During the planning stages, the treatment effect of PEG on survival rate should be conducted according to nutritional status, while most of the included studies did not provide the information regarding the nutritional status and other baseline characteristics of ALS patients. Furthermore, ALS patients can have hypermetabolism, thus the caloric requirements of patients can contribute to the lower energy intake than energy expenditure [<xref ref-type="bibr" rid="pone.0192243.ref037">37</xref>].</p>
<p>Although subgroup analysis suggested prominent therapeutic effects of PEG in studies published before 2005, and in studies with a retrospective design, sample size &lt;100, mean age &lt;60.0 years, and percentage of male patients ≥50.0% for 20-month survival rate in ALS patients, no significant difference between various subgroups was observed. The potential reason for the studies conducted before 2005 was associated with different nutritional status. In addition, our study patients from different countries were correlated with nutritional status, while all the included studies were conducted in highly developed countries. Additionally, the study design and sample size were correlated with evidence level and statistical power. Finally, these factors might disprove the significant impact on 20-month survival in ALS patients administered with PEG. Also, the number of studies included in these subsets was very small, with lower event rates than expected, yielding broad confidence intervals, i.e. no statistically significant differences.</p>
<p>The present study has few limitations which are as follows: (1) several important factors, including general characteristics and clinical conditions affecting the survival rates at different follow-up durations, were not adjusted; (2) based on the published studies, publication bias was an inevitable problem in this analysis; (3) pooled data were used for analysis (individual data were not available), which restricted us from performing a substantially detailed analyses with more comprehensive results.</p>
<p>In conclusion, the current findings suggest that PEG significantly increases 20-month survival rates in ALS patients, with no significant effect on 30-day, 10-month, and 30-month survival rates. These results are consistent, and PEG should be recommended for ALS patients. Future large scale randomized controlled trials are required to confirm the therapeutic effects of PEG on survival rates in ALS patients.</p>
</sec>
<sec id="sec008">
<title>Supporting information</title>
<supplementary-material id="pone.0192243.s001" mimetype="application/msword" position="float" xlink:href="info:doi/10.1371/journal.pone.0192243.s001" xlink:type="simple">
<label>S1 Checklist</label>
<caption>
<title>PRISMA checklist.</title>
<p>(DOC)</p>
</caption>
</supplementary-material>
<supplementary-material id="pone.0192243.s002" mimetype="application/msword" position="float" xlink:href="info:doi/10.1371/journal.pone.0192243.s002" xlink:type="simple">
<label>S1 File</label>
<caption>
<title>The detailed search strategy in PubMed.</title>
<p>(DOC)</p>
</caption>
</supplementary-material>
<supplementary-material id="pone.0192243.s003" mimetype="application/msword" position="float" xlink:href="info:doi/10.1371/journal.pone.0192243.s003" xlink:type="simple">
<label>S1 Table</label>
<caption>
<title>Meta-regression for investigated outcomes according to sample size, mean age, and percentage male.</title>
<p>(DOC)</p>
</caption>
</supplementary-material>
</sec>
</body>
<back>
<ref-list>
<title>References</title>
<ref id="pone.0192243.ref001"><label>1</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lee</surname> <given-names>JR</given-names></name>, <name name-style="western"><surname>Annegers</surname> <given-names>JF</given-names></name>, <name name-style="western"><surname>Appel</surname> <given-names>SH</given-names></name>. <article-title>Prognosis of amyotrophic lateral sclerosis and the effect of referral selection</article-title>. <source>J Neurol Sci</source>. <year>1995</year>;<volume>132</volume>(<issue>2</issue>):<fpage>207</fpage>–<lpage>15</lpage>. <object-id pub-id-type="pmid">8543950</object-id></mixed-citation></ref>
<ref id="pone.0192243.ref002"><label>2</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Preux</surname> <given-names>PM</given-names></name>, <name name-style="western"><surname>Couratier</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Boutros-Toni</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Salle</surname> <given-names>JY</given-names></name>, <name name-style="western"><surname>Tabaraud</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Bernet-Bernady</surname> <given-names>P</given-names></name>, <etal>et al</etal>. <article-title>Survival prediction in sporadic amyotrophic lateral sclerosis. Age and clinical form at onset are independent risk factors</article-title>. <source>Neuroepidemiology</source>. <year>1996</year>;<volume>15</volume>(<issue>3</issue>):<fpage>153</fpage>–<lpage>60</lpage>. <object-id pub-id-type="pmid">8700307</object-id></mixed-citation></ref>
<ref id="pone.0192243.ref003"><label>3</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Traynor</surname> <given-names>BJ</given-names></name>, <name name-style="western"><surname>Codd</surname> <given-names>MB</given-names></name>, <name name-style="western"><surname>Corr</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Forde</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Frost</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Hardiman</surname> <given-names>OM</given-names></name>. <article-title>Clinical features of amyotrophic lateral sclerosis according to the El Escorial and Airlie House diagnostic criteria: A population-based study</article-title>. <source>Arch Neurol</source>. <year>2000</year>;<volume>57</volume>(<issue>8</issue>):<fpage>1171</fpage>–<lpage>6</lpage>. <object-id pub-id-type="pmid">10927797</object-id></mixed-citation></ref>
<ref id="pone.0192243.ref004"><label>4</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>McDermott</surname> <given-names>CJ</given-names></name>, <name name-style="western"><surname>Shaw</surname> <given-names>PJ</given-names></name>. <article-title>Diagnosis and management of motor neurone disease</article-title>. <source>BMJ</source>. <year>2008</year>;<volume>336</volume>(<issue>7645</issue>):<fpage>658</fpage>–<lpage>62</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1136/bmj.39493.511759.BE" xlink:type="simple">10.1136/bmj.39493.511759.BE</ext-link></comment> <object-id pub-id-type="pmid">18356234</object-id></mixed-citation></ref>
<ref id="pone.0192243.ref005"><label>5</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Desport</surname> <given-names>JC</given-names></name>, <name name-style="western"><surname>Preux</surname> <given-names>PM</given-names></name>, <name name-style="western"><surname>Truong</surname> <given-names>TC</given-names></name>, <name name-style="western"><surname>Vallat</surname> <given-names>JM</given-names></name>, <name name-style="western"><surname>Sautereau</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Couratier</surname> <given-names>P</given-names></name>. <article-title>Nutritional status is a prognostic factor for survival in ALS patients</article-title>. <source>Neurology</source>. <year>1999</year>;<volume>53</volume>(<issue>5</issue>):<fpage>1059</fpage>–<lpage>63</lpage>. <object-id pub-id-type="pmid">10496266</object-id></mixed-citation></ref>
<ref id="pone.0192243.ref006"><label>6</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Christensen</surname> <given-names>PB</given-names></name>, <name name-style="western"><surname>Hojer-Pedersen</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Jensen</surname> <given-names>NB</given-names></name>. <article-title>Survival of patients with amyotrophic lateral sclerosis in 2 Danish counties</article-title>. <source>Neurology</source>. <year>1990</year>;<volume>40</volume>(<issue>4</issue>):<fpage>600</fpage>–<lpage>4</lpage>. <object-id pub-id-type="pmid">2320232</object-id></mixed-citation></ref>
<ref id="pone.0192243.ref007"><label>7</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Norris</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Shepherd</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Denys</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>U</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Mukai</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Elias</surname> <given-names>L</given-names></name>, <etal>et al</etal>. <article-title>Onset, natural history and outcome in idiopathic adult motor neuron disease</article-title>. <source>J Neurol Sci</source>. <year>1993</year>;<volume>118</volume>(<issue>1</issue>):<fpage>48</fpage>–<lpage>55</lpage>. <object-id pub-id-type="pmid">8229050</object-id></mixed-citation></ref>
<ref id="pone.0192243.ref008"><label>8</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lopes</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Russell</surname> <given-names>DM</given-names></name>, <name name-style="western"><surname>Whitwell</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Jeejeebhoy</surname> <given-names>KN</given-names></name>. <article-title>Skeletal muscle function in malnutrition</article-title>. <source>Am J Clin Nutr</source>. <year>1982</year>;<volume>36</volume>(<issue>4</issue>):<fpage>602</fpage>–<lpage>10</lpage>. <object-id pub-id-type="pmid">6812409</object-id></mixed-citation></ref>
<ref id="pone.0192243.ref009"><label>9</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rigaud</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Moukaddem</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Cohen</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Malon</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Reveillard</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Mignon</surname> <given-names>M</given-names></name>. <article-title>Refeeding improves muscle performance without normalization of muscle mass and oxygen consumption in anorexia nervosa patients</article-title>. <source>Am J Clin Nutr</source>. <year>1997</year>;<volume>65</volume>(<issue>6</issue>):<fpage>1845</fpage>–<lpage>51</lpage>. <object-id pub-id-type="pmid">9174482</object-id></mixed-citation></ref>
<ref id="pone.0192243.ref010"><label>10</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mazzini</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Corra</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Zaccala</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Mora</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Del Piano</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Galante</surname> <given-names>M</given-names></name>. <article-title>Percutaneous endoscopic gastrostomy and enteral nutrition in amyotrophic lateral sclerosis</article-title>. <source>J Neurol</source>. <year>1995</year>;<volume>242</volume>(<issue>10</issue>):<fpage>695</fpage>–<lpage>8</lpage>. <object-id pub-id-type="pmid">8568533</object-id></mixed-citation></ref>
<ref id="pone.0192243.ref011"><label>11</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mitsumoto</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Davidson</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Moore</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Gad</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Brandis</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Ringel</surname> <given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Percutaneous endoscopic gastrostomy (PEG) in patients with ALS and bulbar dysfunction</article-title>. <source>Amyotroph Lateral Scler Other Motor Neuron Disord</source>. <year>2003</year>;<volume>4</volume>(<issue>3</issue>):<fpage>177</fpage>–<lpage>85</lpage>. <object-id pub-id-type="pmid">13129795</object-id></mixed-citation></ref>
<ref id="pone.0192243.ref012"><label>12</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Russell</surname> <given-names>TR</given-names></name>, <name name-style="western"><surname>Brotman</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Norris</surname> <given-names>F</given-names></name>. <article-title>Percutaneous gastrostomy. A new simplified and cost-effective technique</article-title>. <source>Am J Surg</source>. <year>1984</year>;<volume>148</volume>(<issue>1</issue>):<fpage>132</fpage>–<lpage>7</lpage>. <object-id pub-id-type="pmid">6430111</object-id></mixed-citation></ref>
<ref id="pone.0192243.ref013"><label>13</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bradley</surname> <given-names>WG</given-names></name>, <name name-style="western"><surname>Anderson</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Bromberg</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Gutmann</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Harati</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Ross</surname> <given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Current management of ALS: comparison of the ALS CARE Database and the AAN Practice Parameter. The American Academy of Neurology</article-title>. <source>Neurology</source>. <year>2001</year>;<volume>57</volume>(<issue>3</issue>):<fpage>500</fpage>–<lpage>4</lpage>. <object-id pub-id-type="pmid">11502920</object-id></mixed-citation></ref>
<ref id="pone.0192243.ref014"><label>14</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mitchell</surname> <given-names>SL</given-names></name>, <name name-style="western"><surname>Tetroe</surname> <given-names>JM</given-names></name>. <article-title>Survival after percutaneous endoscopic gastrostomy placement in older persons</article-title>. <source>J Gerontol A Biol Sci Med Sci</source>. <year>2000</year>;<volume>55</volume>(<issue>12</issue>):<fpage>M735</fpage>–<lpage>9</lpage>. <object-id pub-id-type="pmid">11129395</object-id></mixed-citation></ref>
<ref id="pone.0192243.ref015"><label>15</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Moher</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Liberati</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Tetzlaff</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Altman</surname> <given-names>DG</given-names></name>. <article-title>Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement</article-title>. <source>PLoS Med</source>. <year>2009</year>;<volume>6</volume>(<issue>7</issue>):<fpage>e1000097</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pmed.1000097" xlink:type="simple">10.1371/journal.pmed.1000097</ext-link></comment> <object-id pub-id-type="pmid">19621072</object-id></mixed-citation></ref>
<ref id="pone.0192243.ref016"><label>16</label><mixed-citation publication-type="book" xlink:type="simple"><name name-style="western"><surname>Wells</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Shea</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>O'Connell</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Peterson</surname> <given-names>j</given-names></name>, <name name-style="western"><surname>Welch</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Losos</surname> <given-names>M</given-names></name>, <etal>et al</etal>. <source>The Newcastle–Ottawa Scale (NOS) for assessing the quality of non-randomized studies in meta-analysis</source>. <publisher-loc>Ottawa (ON)</publisher-loc>: <publisher-name>Ottawa Hospital Research Institute</publisher-name> <year>2009</year>; 2000. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm" xlink:type="simple">http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm</ext-link>.</mixed-citation></ref>
<ref id="pone.0192243.ref017"><label>17</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>DerSimonian</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Laird</surname> <given-names>N</given-names></name>. <article-title>Meta-analysis in clinical trials</article-title>. <source>Control Clin Trials</source>. <year>1986</year>;<volume>7</volume>(<issue>3</issue>):<fpage>177</fpage>–<lpage>88</lpage>. <object-id pub-id-type="pmid">3802833</object-id></mixed-citation></ref>
<ref id="pone.0192243.ref018"><label>18</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ades</surname> <given-names>AE</given-names></name>, <name name-style="western"><surname>Lu</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Higgins</surname> <given-names>JP</given-names></name>. <article-title>The interpretation of random-effects meta-analysis in decision models</article-title>. <source>Med Decis Making</source>. <year>2005</year>;<volume>25</volume>(<issue>6</issue>):<fpage>646</fpage>–<lpage>54</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1177/0272989X05282643" xlink:type="simple">10.1177/0272989X05282643</ext-link></comment> <object-id pub-id-type="pmid">16282215</object-id></mixed-citation></ref>
<ref id="pone.0192243.ref019"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Deeks JJ, Higgins JPT, Altman DG. Analyzing data and undertaking meta-analyses. In: Higgins J, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 501. Oxford, UK: The Cochrane Collaboration; 2008. pp. chap 9.</mixed-citation></ref>
<ref id="pone.0192243.ref020"><label>20</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Higgins</surname> <given-names>JP</given-names></name>, <name name-style="western"><surname>Thompson</surname> <given-names>SG</given-names></name>, <name name-style="western"><surname>Deeks</surname> <given-names>JJ</given-names></name>, <name name-style="western"><surname>Altman</surname> <given-names>DG</given-names></name>. <article-title>Measuring inconsistency in meta-analyses</article-title>. <source>BMJ</source>. <year>2003</year>;<volume>327</volume>(<issue>7414</issue>):<fpage>557</fpage>–<lpage>60</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1136/bmj.327.7414.557" xlink:type="simple">10.1136/bmj.327.7414.557</ext-link></comment> <object-id pub-id-type="pmid">12958120</object-id></mixed-citation></ref>
<ref id="pone.0192243.ref021"><label>21</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Tobias</surname> <given-names>A</given-names></name>. <article-title>Assessing the influence of a single study in meta-analysis</article-title>. <source>Stata Tech Bull</source>. <year>1999</year>;<volume>47</volume>:<fpage>15</fpage>–<lpage>7</lpage>.</mixed-citation></ref>
<ref id="pone.0192243.ref022"><label>22</label><mixed-citation publication-type="book" xlink:type="simple"><name name-style="western"><surname>Deeks</surname> <given-names>JJ</given-names></name>, <name name-style="western"><surname>Altman</surname> <given-names>DG</given-names></name>, <name name-style="western"><surname>Bradburn</surname> <given-names>MJ</given-names></name>. <chapter-title>Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis</chapter-title>. In: <name name-style="western"><surname>Egger</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>G.</surname> <given-names>DS</given-names></name>, <name name-style="western"><surname>Altman</surname> <given-names>DG</given-names></name>, editors. <source>Systematic Reviews in Health Care: Metaanalysis in Context</source>. <edition>2nd ed.</edition> <publisher-loc>London</publisher-loc>: <publisher-name>BMJ Books</publisher-name>; <year>2001</year>. pp. <fpage>285</fpage>–<lpage>312</lpage>.</mixed-citation></ref>
<ref id="pone.0192243.ref023"><label>23</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Egger</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Davey Smith</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Schneider</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Minder</surname> <given-names>C</given-names></name>. <article-title>Bias in meta-analysis detected by a simple, graphical test</article-title>. <source>BMJ</source>. <year>1997</year>;<volume>315</volume>(<issue>7109</issue>):<fpage>629</fpage>–<lpage>34</lpage>. <object-id pub-id-type="pmid">9310563</object-id></mixed-citation></ref>
<ref id="pone.0192243.ref024"><label>24</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Begg</surname> <given-names>CB</given-names></name>, <name name-style="western"><surname>Mazumdar</surname> <given-names>M</given-names></name>. <article-title>Operating characteristics of a rank correlation test for publication bias</article-title>. <source>Biometrics</source>. <year>1994</year>;<volume>50</volume>(<issue>4</issue>):<fpage>1088</fpage>–<lpage>101</lpage>. <object-id pub-id-type="pmid">7786990</object-id></mixed-citation></ref>
<ref id="pone.0192243.ref025"><label>25</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Shaw</surname> <given-names>AS</given-names></name>, <name name-style="western"><surname>Ampong</surname> <given-names>MA</given-names></name>, <name name-style="western"><surname>Rio</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Al-Chalabi</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Sellars</surname> <given-names>ME</given-names></name>, <name name-style="western"><surname>Ellis</surname> <given-names>C</given-names></name>, <etal>et al</etal>. <article-title>Survival of patients with ALS following institution of enteral feeding is related to pre-procedure oximetry: a retrospective review of 98 patients in a single centre</article-title>. <source>Amyotroph Lateral Scler</source>. <year>2006</year>;<volume>7</volume>(<issue>1</issue>):<fpage>16</fpage>–<lpage>21</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1080/14660820510012013" xlink:type="simple">10.1080/14660820510012013</ext-link></comment> <object-id pub-id-type="pmid">16546754</object-id></mixed-citation></ref>
<ref id="pone.0192243.ref026"><label>26</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mathus-Vliegen</surname> <given-names>LM</given-names></name>, <name name-style="western"><surname>Louwerse</surname> <given-names>LS</given-names></name>, <name name-style="western"><surname>Merkus</surname> <given-names>MP</given-names></name>, <name name-style="western"><surname>Tytgat</surname> <given-names>GN</given-names></name>, <name name-style="western"><surname>Vianney de Jong</surname> <given-names>JM</given-names></name>. <article-title>Percutaneous endoscopic gastrostomy in patients with amyotrophic lateral sclerosis and impaired pulmonary function</article-title>. <source>Gastrointest Endosc</source>. <year>1994</year>;<volume>40</volume>(<issue>4</issue>):<fpage>463</fpage>–<lpage>9</lpage>. <object-id pub-id-type="pmid">7926537</object-id></mixed-citation></ref>
<ref id="pone.0192243.ref027"><label>27</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Spataro</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Ficano</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Piccoli</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>La Bella</surname> <given-names>V</given-names></name>. <article-title>Percutaneous endoscopic gastrostomy in amyotrophic lateral sclerosis: effect on survival</article-title>. <source>J Neurol Sci</source>. <year>2011</year>;<volume>304</volume>(<issue>1–2</issue>):<fpage>44</fpage>–<lpage>8</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jns.2011.02.016" xlink:type="simple">10.1016/j.jns.2011.02.016</ext-link></comment> <object-id pub-id-type="pmid">21371720</object-id></mixed-citation></ref>
<ref id="pone.0192243.ref028"><label>28</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Blondet</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Lebigot</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Nicolas</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Boursier</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Person</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Laccoureye</surname> <given-names>L</given-names></name>, <etal>et al</etal>. <article-title>Radiologic versus endoscopic placement of percutaneous gastrostomy in amyotrophic lateral sclerosis: multivariate analysis of tolerance, efficacy, and survival</article-title>. <source>J Vasc Interv Radiol</source>. <year>2010</year>;<volume>21</volume>(<issue>4</issue>):<fpage>527</fpage>–<lpage>33</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jvir.2009.11.022" xlink:type="simple">10.1016/j.jvir.2009.11.022</ext-link></comment> <object-id pub-id-type="pmid">20172742</object-id></mixed-citation></ref>
<ref id="pone.0192243.ref029"><label>29</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Thornton</surname> <given-names>FJ</given-names></name>, <name name-style="western"><surname>Fotheringham</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Alexander</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Hardiman</surname> <given-names>O</given-names></name>, <name name-style="western"><surname>McGrath</surname> <given-names>FP</given-names></name>, <name name-style="western"><surname>Lee</surname> <given-names>MJ</given-names></name>. <article-title>Amyotrophic lateral sclerosis: enteral nutrition provision—endoscopic or radiologic gastrostomy?</article-title> <source>Radiology</source>. <year>2002</year>;<volume>224</volume>(<issue>3</issue>):<fpage>713</fpage>–<lpage>7</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1148/radiol.2243010909" xlink:type="simple">10.1148/radiol.2243010909</ext-link></comment> <object-id pub-id-type="pmid">12202704</object-id></mixed-citation></ref>
<ref id="pone.0192243.ref030"><label>30</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Allen</surname> <given-names>JA</given-names></name>, <name name-style="western"><surname>Chen</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Ajroud-Driss</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Sufit</surname> <given-names>RL</given-names></name>, <name name-style="western"><surname>Heller</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Siddique</surname> <given-names>T</given-names></name>, <etal>et al</etal>. <article-title>Gastrostomy tube placement by endoscopy versus radiologic methods in patients with ALS: a retrospective study of complications and outcome</article-title>. <source>Amyotroph Lateral Scler Frontotemporal Degener</source>. <year>2013</year>;<volume>14</volume>(<issue>4</issue>):<fpage>308</fpage>–<lpage>14</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3109/21678421.2012.751613" xlink:type="simple">10.3109/21678421.2012.751613</ext-link></comment> <object-id pub-id-type="pmid">23286755</object-id></mixed-citation></ref>
<ref id="pone.0192243.ref031"><label>31</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Desport</surname> <given-names>JC</given-names></name>, <name name-style="western"><surname>Mabrouk</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Bouillet</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Perna</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Preux</surname> <given-names>PM</given-names></name>, <name name-style="western"><surname>Couratier</surname> <given-names>P</given-names></name>. <article-title>Complications and survival following radiologically and endoscopically-guided gastrostomy in patients with amyotrophic lateral sclerosis</article-title>. <source>Amyotroph Lateral Scler Other Motor Neuron Disord</source>. <year>2005</year>;<volume>6</volume>(<issue>2</issue>):<fpage>88</fpage>–<lpage>93</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1080/14660820410021258" xlink:type="simple">10.1080/14660820410021258</ext-link></comment> <object-id pub-id-type="pmid">16036431</object-id></mixed-citation></ref>
<ref id="pone.0192243.ref032"><label>32</label><mixed-citation publication-type="journal" xlink:type="simple"><collab>ProGas Study Group</collab>. <article-title>Gastrostomy in patients with amyotrophic lateral sclerosis (ProGas): a prospective cohort study</article-title>. <source>Lancet Neurol</source>. <year>2015</year>;<volume>14</volume>(<issue>7</issue>):<fpage>702</fpage>–<lpage>9</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/S1474-4422(15)00104-0" xlink:type="simple">10.1016/S1474-4422(15)00104-0</ext-link></comment> <object-id pub-id-type="pmid">26027943</object-id></mixed-citation></ref>
<ref id="pone.0192243.ref033"><label>33</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Chio</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Galletti</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Finocchiaro</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Righi</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Ruffino</surname> <given-names>MA</given-names></name>, <name name-style="western"><surname>Calvo</surname> <given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Percutaneous radiological gastrostomy: a safe and effective method of nutritional tube placement in advanced ALS</article-title>. <source>J Neurol Neurosurg Psychiatry</source>. <year>2004</year>;<volume>75</volume>(<issue>4</issue>):<fpage>645</fpage>–<lpage>7</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1136/jnnp.2003.020347" xlink:type="simple">10.1136/jnnp.2003.020347</ext-link></comment> <object-id pub-id-type="pmid">15026518</object-id></mixed-citation></ref>
<ref id="pone.0192243.ref034"><label>34</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Desport</surname> <given-names>JC</given-names></name>, <name name-style="western"><surname>Torny</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Lacoste</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Preux</surname> <given-names>PM</given-names></name>, <name name-style="western"><surname>Couratier</surname> <given-names>P</given-names></name>. <article-title>Hypermetabolism in ALS: correlations with clinical and paraclinical parameters</article-title>. <source>Neurodegener Dis</source>. <year>2005</year>;<volume>2</volume>(<issue>3–4</issue>):<fpage>202</fpage>–<lpage>7</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1159/000089626" xlink:type="simple">10.1159/000089626</ext-link></comment> <object-id pub-id-type="pmid">16909026</object-id></mixed-citation></ref>
<ref id="pone.0192243.ref035"><label>35</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bouteloup</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Desport</surname> <given-names>JC</given-names></name>, <name name-style="western"><surname>Clavelou</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Guy</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Derumeaux-Burel</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Ferrier</surname> <given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Hypermetabolism in ALS patients: an early and persistent phenomenon</article-title>. <source>J Neurol</source>. <year>2009</year>;<volume>256</volume>(<issue>8</issue>):<fpage>1236</fpage>–<lpage>42</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s00415-009-5100-z" xlink:type="simple">10.1007/s00415-009-5100-z</ext-link></comment> <object-id pub-id-type="pmid">19306035</object-id></mixed-citation></ref>
<ref id="pone.0192243.ref036"><label>36</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Vaisman</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Lusaus</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Nefussy</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Niv</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Comaneshter</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Hallack</surname> <given-names>R</given-names></name>, <etal>et al</etal>. <article-title>Do patients with amyotrophic lateral sclerosis (ALS) have increased energy needs?</article-title> <source>J Neurol Sci</source>. <year>2009</year>;<volume>279</volume>(<issue>1–2</issue>):<fpage>26</fpage>–<lpage>9</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jns.2008.12.027" xlink:type="simple">10.1016/j.jns.2008.12.027</ext-link></comment> <object-id pub-id-type="pmid">19185883</object-id></mixed-citation></ref>
<ref id="pone.0192243.ref037"><label>37</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Genton</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Viatte</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Janssens</surname> <given-names>JP</given-names></name>, <name name-style="western"><surname>Heritier</surname> <given-names>AC</given-names></name>, <name name-style="western"><surname>Pichard</surname> <given-names>C</given-names></name>. <article-title>Nutritional state, energy intakes and energy expenditure of amyotrophic lateral sclerosis (ALS) patients</article-title>. <source>Clin Nutr</source>. <year>2011</year>;<volume>30</volume>(<issue>5</issue>):<fpage>553</fpage>–<lpage>9</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.clnu.2011.06.004" xlink:type="simple">10.1016/j.clnu.2011.06.004</ext-link></comment> <object-id pub-id-type="pmid">21798636</object-id></mixed-citation></ref>
</ref-list>
</back>
</article>